We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vivoryon Therapeutics NV (VVY) NPV

Sell:€1.95 Buy:€2.00 Change: €0.012 (0.61%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€1.95
Buy:€2.00
Change: €0.012 (0.61%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€1.95
Buy:€2.00
Change: €0.012 (0.61%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.

Contact details

Address:
Weinbergweg 22
HALLE
06120
Germany
Telephone:
+49 (345) 5559900
Website:
https://www.vivoryon.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VVY
ISIN:
NL00150002Q7
Market cap:
€51.09 million
Shares in issue:
26.07 million
Sector:
Biotechnology
Exchange:
Euronext Amsterdam
Country:
Netherlands
Currency:
Euro
Indices:
n/a

Key personnel

  • Frank Weber
    Chief Executive Officer, Executive Director, Chief Medical Officer
  • Anne Doering
    Chief Financial Officer, Executive Director
  • Michael Schaeffer
    Chief Business Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.